Healthcare spending slowdown continues

Laura Pedulli | | Health Exec | Policy & Regulations

Healthcare spending growth remained at a near-record low for the fourth consecutive year, according to a report from the Centers for Medicare and Medicaid Services’ Office of the Actuary.

In 2012, healthcare spending rose by 3.7 percent to $2.8 trillion—with the average cost of medical care per person at $8,915 in 2012 versus $8,658 in 2011. Meanwhile, healthcare spending as a portion of the overall U.S. economy dipped slightly from 17.3 percent in 2011 to 17.2 percent in 2012, according to the analysis.

"The relative stability since 2009 primarily reflects the lagged impact of the recent severe economic recession," said Anne Martin, an economist at CMS, according to Reuters.

Details of the analysis can be found here.

 

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.